Marc Sabatine
Physician · Massachusetts General Hospital
Credentials: · · · ·
History
- 2019–Present
- 1999–2002
- 1991–1995
Research
European Heart Journal · 2020 · 6,964 citations
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
New England Journal of Medicine · 2019 · 5,443 citations
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
New England Journal of Medicine · 2019 · 4,800 citations
- DM
151 papers · 7 as a fellow
- EB
144 papers
- RG
140 papers
- SW
125 papers
90 papers
89 papers
- SS
87 papers
86 papers
Grants
- 2013–2019
National Center for Advancing Translational Sciences · UH3
PI · $3.2M · Massachusetts General Hospital
- 2010–2016
Metabolomic Biomarkers of Early Myocardial Injury
National Heart, Lung, and Blood Institute · R01
PI · $3.7M · Massachusetts General Hospital
- 2013–2015
Optimization of Biofluid Ex-RNA Isolation and Characterization.
National Center for Advancing Translational Sciences · UH2
PI · $1.1M · Beth Israel Deaconess Medical Center
- 2009–2014
Discovery & Application of Proteomics-Based Biomarkers of Early Myocardial Injury
National Heart, Lung, and Blood Institute · R01
PI · $2.9M · Massachusetts General Hospital
Clinical trials
- 2010–2014
Principal investigator · Completed · Phase 3
AstraZeneca
- 2020–2022
Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
Study chair · Completed · Phase 4
The TIMI Study Group
- 2013–2018
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
Study chair · Completed · Phase 3
AstraZeneca